রাজডক - Rajdoc
Banolata-2023-03-09.gif
Banolata-2024-03-09.gif

ডাঃ এর সিরিয়াল দিন

Axicef 500mg

Tablet
Cefuroxime Axetil
Unimed Unihealth MFG. Ltd

Other Strength:
- Axicef 250mg

Alternative:
- Cefotil® 500mg
- Furotil 500mg
- Cefobac 500mg
- Cerox-A Tablet 500mg
- Xitil 500mg
- Roximax 500mg
- Axetil 500mg
- Axefur 500mg
- Axim 500mg
- C-2 500mg
- Benkill 500mg
- Famicef 500mg
- Furocef 500mg



Axicef
Presentation

Axicef 250 tablet: White, capsule shaped, breakline on one side, film coated tablet; each tablet contains Cefuroxime Axetil BP equivalent to Cefuroxime 250 mg

Axicef 500 tablet: White, capsule shaped, film coated tablet; each tablet contains Cefuroxime Axetil BP equivalent to Cefuroxime 500 mg

Axicef suspension: White, Tutti-frutti flavoured powder for Suspension; after reconstitution each 5 ml suspension contains Cefuroxime Axetil BP equivalent to Cefuroxime 125 mg

Indication

Axicef (Cefuroxime Axetil) is Indicated for the treatment of Acute streptococcal tonsillitis and pharyngitis, Acute bacterial sinusitis, Acute otitis media, Acute exacerbations of chronic bronchitis, Cystitis, Pyelonephritis, Uncomplicated skin and soft tissue infections & early Lyme disease in adults and children (³3 months)

Dosage and Administration

The usual course of Axicef (Cefuroxime Axetil) is seven days (may range from five to ten days).
There is no experience of using Axicef (Cefuroxime Axetil) in children under the age of 3 months.

Renal impairment: The safety and efficacy of Axicef (Cefuroxime Axetil) in patients with renal failure have not been established. Axicef (Cefuroxime Axetil) is primarily excreted by the kidneys. In patients with markedly impaired renal function it is recommended that the dosage of Axicef (Cefuroxime Axetil) should be reduced to compensate for its slower excretion. Axicef (Cefuroxime Axetil) is effectively removed by dialysis.

Hepatic impairment: There are no data available for patients with hepatic impairment. Since Axicef (Cefuroxime Axetil)is primarily eliminated by the kidney, the presence of hepatic dysfunction is expected to have no effect on the pharmacokinetics of Axicef (Cefuroxime Axetil).

Method of administration: Oral use: Axicef (Cefuroxime Axetil) tablets should be taken after food for optimum absorption.

Contra-indication, warnings etc

Contra-indication: Patients with known hypersensitivity to cephalosporin antibiotics. History of severe hypersensitivity to any other type of betalactam antibacterial agent (penicillins, monobactams and carbapenems).

Warnings and precautions: Hypersensitivity reactions: Special care is indicated in patients who have experienced an allergic reaction to penicillins or other beta-lactam antibiotics because there is a risk of cross-sensitivity. As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions have been reported. In case of severe hypersensitivity reactions, treatment with cefuroxime must be discontinued immediately and adequate emergency measures must be initiated. Before beginning treatment, it should be established whether the patient has a history of severe hypersensitivity reactions to cefuroxime, to other cephalosporins or to any other type of beta-lactam agent. Caution should be used if cefuroxime is given to patients with a history of non-severe hypersensitivity to other beta-lactam agents. Jarisch-Herxheimer reaction: The Jarisch-Herxheimer reaction has been seen following cefuroxime axetil treatment of Lyme disease. It results directly from the bactericidal activity of cefuroxime axetil on the causative bacteria of Lyme disease, the spirochaete Borrelia burgdorferi. Patients should be reassured that this is a common and usually self-limiting consequence of antibiotic treatment of Lyme disease. Overgrowth of non-susceptible microorganisms: As with other antibiotics, use of cefuroxime Axetil may result in the overgrowth of Candida. Prolonged use may also result in the overgrowth of other non-susceptible microorganisms (e.g. enterococci and Clostridium difficile), which may require interruption of treatment. Antibacterial agent-associated
pseudomembranous colitis have been reported with nearly all antibacterial agents, including cefuroxime and may range in severity from mild to life threatening. This diagnosis should be considered in patients with diarrhoea during or subsequent to the administration of cefuroxime. Discontinuation of therapy with cefuroxime and the administration of specific treatment for Clostridium difficile should be considered. Medicinal products that inhibit peristalsis should not be given. Interference with diagnostic tests: The development of a positive Coomb’s Test associated with the use of cefuroxime may interfere with cross matching of blood. As a false negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase methods are used to determine blood/plasma glucose levels in patients receiving cefuroxime Axetil.

Drug Interactions: Drugs which reduce gastric acidity may result in a lower bioavailability of cefuroxime axetil compared with that of the fasting state and tend to cancel the effect of enhanced absorption after food. Cefuroxime is excreted by glomerular filtration and tubular secretion. Concomitant use of probenecid is not recommended. Concurrent administration of probenecid significantly increases the peak concentration, area under the serum concentration time curve and elimination half-life of Cefuroxime. Concomitant use with oral anticoagulants may give rise to increased INR.

Use in pregnancy and lactation: Pregnancy: Pregnancy category B. There are limited data from the use of cefuroxime in pregnant women. Studies in animals have shown no harmful effects on pregnancy, embryonal or foetal development, parturition or postnatal development. Cefuroxime Axetil should be prescribed to pregnant women only if the benefit outweighs the risk. Breastfeeding: Cefuroxime is excreted in human milk in small quantities. Adverse effects at therapeutic doses are not expected, although a risk of diarrhoea and fungus infection of the mucous membranes cannot be excluded. Breastfeeding might have to be discontinued due to these effects. The possibility of sensitisation should be taken into account. Cefuroxime should only be used during breastfeeding after benefit/risk assessment by the physician in charge. Fertility: There are no data on the effects of Cefuroxime Axetil on fertility in humans. Reproductive studies in animals have shown no effects on fertility.

Effects on ability to drive and use machines: No studies on the effects on the ability to drive and use machines have been performed. However, as this medicine may cause dizziness, patients should be warned to be cautious when driving or operating machinery.

Overdose: Overdose can lead to neurological sequelae including encephalopathy, convulsions and coma. Symptoms of overdose can occur if the dose is not reduced appropriately in patients with renal impairment. Serum levels of cefuroxime can be reduced by haemodialysis and peritoneal dialysis.

Direction for reconstitution of powder for suspension: Shake the bottle well so that powder does not clog. Add 45ml (9 x 5ml spoonful) boiled and cooled water to the bottle. Shake well until all powder is dispersed. Reconstituted suspension should be stored between 20 and 80 C in a refrigerator. Discard unused portion after 10 days. Shake the bottle well before each use.

Pharmaceutical precautions

Store in a cool and dry place, protected from light.

Packaging quantities

Axicef 250 tablet: Carton containing of 12 tablets in alu-alu blisters.

Axicef 500 tablet: Carton containing of 8 tablets in blisters.

Axicef suspension: Carton containing powder to produce 70 ml suspension when reconstituted in glass bottle.



এই পাতাটি ১৮০ বার দেখা হয়েছে


যোগাযোগ
প্যারামেডিকেল রোড
লক্ষ্মীপুর, রাজশাহী
Email: info@rajdoc.com
Phone: +8801753226626